Seeking Alpha Interviews: Bret Jensen On Promising Drugs And Acquisition Targets

| About: iShares Nasdaq (IBB)

Summary

Seeking Alpha contributor Bret Jensen weighs in on the biotech and pharma industries.

He highlights recent factors helping biotech indices rally, drug pricing, and the regulatory environment.

Overall, the environment looks favorable for biotech, but the era of major drug price increases appears to be over.

In the fifth episode of Seeking Alpha Interviews, Lilamax's Jane King sits down with Bret Jensen to discuss regulatory changes, merger activity, and drug development affecting action in the biotech sector.

The discussion touches on the new Trump administration's regulatory and tax posture, the potential for midcap pharma stocks as acquisition targets, and what he sees as a favorable year ahead for drug companies.

You can also check out previous episodes of the series featuring Bert Hochfeld, Mott Capital, and Eric Parnell, and another conversation with Bret Jensen.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

About this article:

Expand
Want to share your opinion on this article? Add a comment.
Disagree with this article? .
To report a factual error in this article, click here